We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
In the latest market close, Teladoc (TDOC - Free Report) reached $21.36, with a +0.56% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.34%. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, lost 0.56%.
The telehealth services provider's stock has climbed by 12.02% in the past month, exceeding the Medical sector's gain of 5.72% and the S&P 500's gain of 2.56%.
Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.22, signifying a 4.35% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $670.77 million, up 5.18% from the year-ago period.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.08% lower within the past month. Right now, Teladoc possesses a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
In the latest market close, Teladoc (TDOC - Free Report) reached $21.36, with a +0.56% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.34%. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, lost 0.56%.
The telehealth services provider's stock has climbed by 12.02% in the past month, exceeding the Medical sector's gain of 5.72% and the S&P 500's gain of 2.56%.
Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.22, signifying a 4.35% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $670.77 million, up 5.18% from the year-ago period.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.08% lower within the past month. Right now, Teladoc possesses a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.